When barriers ignore the “rule-of-five”

Advanced Drug Delivery Reviews

Volumn 101, Issue , 2016, Pages 62-74

  Krämer, Stefanie D ^a   Aschmann, Hélène E ^a   Hatibovic, Maja ^a   Hermann, Katharina F ^a   Neuhaus, Claudia S ^a   Brunner, Cyrill ^a   Belli, Sara ^b  

^a ETH ZURICH   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Absorption; Beyond the rule of five; Charge; Drug; Intramolecular H bonds; Lipid bilayer; Permeation

Indexed keywords

ABSORPTION; LIPID BILAYERS; LIPOSOMES; MOLECULAR DYNAMICS; PERMEATION; PHOSPHOLIPIDS; PROTEINS;

BEYOND THE RULE OF FIVE; CHARGE; DRUG; DRUG-DRUG INTERACTIONS; H-BONDS; INTESTINAL MUCOSA; MOLECULAR DYNAMICS SIMULATIONS; PHOSPHOLIPID BILAYER;

DRUG INTERACTIONS;

AMINOPTERIN; BEYOND THE RULE OF FIVE COMPOUND; CYCLOSPORIN A; DEMECLOCYCLINE; DIGOXIN; DOXYCYCLINE; DRUG; FOLIC ACID; LIPOSOME; METACYCLINE; OXYTETRACYCLINE; PSEUDOHYPERICIN; RIFAMPICIN; TETRACYCLINE; UNCLASSIFIED DRUG; LABETALOL; METOPROLOL;

DIFFUSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG STRUCTURE; HUMAN; HYDROGEN BOND; IN VIVO STUDY; INTESTINE ABSORPTION; LIPID BILAYER; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; INTESTINE MUCOSA; METABOLISM;

ANIMALS; HUMANS; HYDROGEN BONDING; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; LABETALOL; LIPID BILAYERS; LIPOSOMES; METOPROLOL; MOLECULAR DYNAMICS SIMULATION; PHARMACEUTICAL PREPARATIONS; RIFAMPIN; TETRACYCLINE;

EID: 84959189674     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.02.001     Document Type: Review

References (74)

1. [1] Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001), 3–26.
2. [2] Alex, A., Millan, D.S., Perez, M., Wakenhut, F., Whitlock, G.A., Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space. Med. Chem. Comm. 2 (2011), 669–674.
3. [3] Doak, B.C., Over, B., Giordanetto, F., Kihlberg, J., Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem. Biol. 21 (2014), 1115–1142.
4. [4] Kozakov, D., Hall, D.R., Napoleon, R.L., Yueh, C., Whitty, A., Vajda, S., New frontiers in druggability. J. Med. Chem., 2015.
5. [5] Stenberg, P., Bergstrom, C.A., Luthman, K., Artursson, P., Theoretical predictions of drug absorption in drug discovery and development. Clin. Pharmacokinet. 41 (2002), 877–899.
6. [6] Smith, D., Artursson, P., Avdeef, A., Di, L., Ecker, G.F., Faller, B., Houston, J.B., Kansy, M., Kerns, E.H., Krämer, S.D., Lennernäs, H., van de Waterbeemd, H., Sugano, K., Testa, B., Passive lipoidal diffusion and carrier-mediated cell uptake are both important mechanisms of membrane permeation in drug disposition. Mol. Pharm. 11 (2014), 1727–1738.
7. [7] Di, L., Artursson, P., Avdeef, A., Ecker, G.F., Faller, B., Fischer, H., Houston, J.B., Kansy, M., Kerns, E.H., Krämer, S.D., Lennernäs, H., Sugano, K., Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. Drug Discov. Today 17 (2012), 905–912.
8. [8] Sugano, K., Theoretical investigation of passive intestinal membrane permeability using Monte Carlo method to generate drug-like molecule population. Int. J. Pharm. 373 (2009), 55–61.
9. [9] Abbott, N.J., Blood–brain barrier structure and function and the challenges for CNS drug delivery. J. Inherit. Metab. Dis. 36 (2013), 437–449.
10. [10] Kell, D.B., Dobson, P.D., Bilsland, E., Oliver, S.G., The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. Drug Discov. Today 18 (2013), 218–239.
11. [11] Sugano, K., Kansy, M., Artursson, P., Avdeef, A., Bendels, S., Di, L., Ecker, G.F., Faller, B., Fischer, H., Gerebtzoff, G., Lennernaes, H., Senner, F., Coexistence of passive and carrier-mediated processes in drug transport. Nat. Rev. Drug Discov. 9 (2010), 597–614.
12. [12] Estudante, M., Morais, J.G., Soveral, G., Benet, L.Z., Intestinal drug transporters: an overview. Adv. Drug Deliv. Rev. 65 (2013), 1340–1356.
13. [13] Dahan, A., Khamis, M., Agbaria, R., Karaman, R., Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach. Expert Opin. Drug Deliv. 9 (2012), 1001–1013.
14. [14] Vijay, N., Morris, M.E., Role of monocarboxylate transporters in drug delivery to the brain. Curr. Pharm. Des. 20 (2014), 1487–1498.
15. [15] Tamai, I., Nakanishi, T., OATP transporter-mediated drug absorption and interaction. Curr. Opin. Pharmacol. 13 (2013), 859–863.
16. [16] Feng, B., Varma, M.V., Costales, C., Zhang, H., Tremaine, L., In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery. Expert Opin. Drug Discov. 9 (2014), 873–890.
17. [17] Smith, D.E., Clemencon, B., Hediger, M.A., Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications. Mol. Asp. Med. 34 (2013), 323–336.
18. [18] Arimany-Nardi, C., Koepsell, H., Pastor-Anglada, M., Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug–drug interactions. Pharmacogenomics J. 15 (2015), 473–487.
19. [19] Russel, F.G.M., Transporters: Importance in Drug Absorption, Distribution, and Removal. Pang, K.S., Rodrigues, A.D., Peter, R.M., (eds.) Enzyme- and Transporter-Based Drug–Drug Interactions: Progress and Future Challenges, 2010, AAPS Press, Springer, Heidelberg.
20. [20] Misaka, S., Muller, F., Fromm, M.F., Clinical relevance of drug efflux pumps in the gut. Curr. Opin. Pharmacol. 13 (2013), 847–852.
21. [21] Sharom, F.J., The P-glycoprotein multidrug transporter. Essays Biochem. 50 (2011), 161–178.
22. [22] Mao, Q., Unadkat, J.D., Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport—an update. AAPS J. 17 (2015), 65–82.
23. [23] Mao, Q., Unadkat, J.D., Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 7 (2005), E118–E133.
24. [24] Maeda, K., Takano, J., Ikeda, Y., Fujita, T., Oyama, Y., Nozawa, K., Kumagai, Y., Sugiyama, Y., Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. Clin. Pharmacol. Ther. 90 (2011), 263–270.
25. [25] Matsson, P., Fenu, L.A., Lundquist, P., Wisniewski, J.R., Kansy, M., Artursson, P., Quantifying the impact of transporters on cellular drug permeability. Trends Pharmacol. Sci. 36 (2015), 255–262.
26. [26] Doppenschmitt, S., Spahn-Langguth, H., Regardh, C.G., Langguth, P., Role of P-glycoprotein-mediated secretion in absorptive drug permeability: an approach using passive membrane permeability and affinity to P-glycoprotein. J. Pharm. Sci. 88 (1999), 1067–1072.
27. [27] Caruso, A., Alvarez-Sanchez, R., Hillebrecht, A., Poirier, A., Schuler, F., Lave, T., Funk, C., Belli, S., PK/PD assessment in CNS drug discovery: prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation. Biochem. Pharmacol. 85 (2013), 1684–1699.
28. [28] Krämer, S.D., Quantitative aspects of drug permeation across in vitro and in vivo barriers. Eur. J. Pharm. Sci., 2015.
29. [29] Raub, T.J., P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol. Pharm. 3 (2006), 3–25.
30. [30] Eyer, K., Herger, M., Krämer, S.D., Dittrich, P.S., Cell-free microfluidic determination of P-glycoprotein interactions with substrates and inhibitors. Pharm. Res. 31 (2014), 3415–3425.
31. [31] Bickerton, G.R., Paolini, G.V., Besnard, J., Muresan, S., Hopkins, A.L., Quantifying the chemical beauty of drugs. Nat. Chem. 4 (2012), 90–98.
32. [32] Guimaraes, C.R., Mathiowetz, A.M., Shalaeva, M., Goetz, G., Liras, S., Use of 3D properties to characterize beyond rule-of-5 property space for passive permeation. J. Chem. Inf. Model. 52 (2012), 882–890.
33. [33] NCBI, PubChem, http://pubchem.ncbi.nlm.nih.gov.
34. [34] FDA, StructuredProductLabeling (SPL), http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling.
35. [35] Hou, Z., Matherly, L.H., Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr. Top. Membr. 73 (2014), 175–204.
36. [36] Visentin, M., Diop-Bove, N., Zhao, R., Goldman, I.D., The intestinal absorption of folates. Annu. Rev. Physiol. 76 (2014), 251–274.
37. [37] Suzuki, M., Komura, H., Yoshikawa, T., Enya, S., Nagao, A., Takubo, H., Kogayu, M., Characterization of gastrointestinal absorption of digoxin involving influx and efflux transporter in rats: application of mdr1a knockout (−/−) rats into absorption study of multiple transporter substrate. Xenobiotica 44 (2014), 1039–1045.
38. [38] Eyer, K., Paech, F., Schuler, F., Kuhn, P., Kissner, R., Belli, S., Dittrich, P.S., Krämer, S.D., A liposomal fluorescence assay to study permeation kinetics of drug-like weak bases across the lipid bilayer. J. Control. Release 173 (2014), 102–109.
39. [39] Mindermann, T., Zimmerli, W., Gratzl, O., Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space. Antimicrob. Agents Chemother. 42 (1998), 2626–2629.
40. [40] Woo, J., Cheung, W., Chan, R., Chan, H.S., Cheng, A., Chan, K., In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein. Clin. Biochem. 29 (1996), 175–177.
41. [41] Mariappan, T.T., Singh, S., Evidence of efflux-mediated and saturable absorption of rifampicin in rat intestine using the ligated loop and everted gut sac techniques. Mol. Pharm. 1 (2004), 363–367.
42. [42] Hosagrahara, V., Reddy, J., Ganguly, S., Panduga, V., Ahuja, V., Parab, M., Giridhar, J., Effect of repeated dosing on rifampin exposure in BALB/c mice. Eur. J. Pharm. Sci. 49 (2013), 33–38.
43. [43] Schuetz, E.G., Schinkel, A.H., Relling, M.V., Schuetz, J.D., P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 4001–4005.
44. [44] Kuhn, B., Mohr, P., Stahl, M., Intramolecular hydrogen bonding in medicinal chemistry. J. Med. Chem. 53 (2010), 2601–2611.
45. [45] Bemporad, D., Luttmann, C., Essex, J.W., Behaviour of small solutes and large drugs in a lipid bilayer from computer simulations. Biochim. Biophys. Acta 1718 (2005), 1–21.
46. [46] Goni, F.M., The basic structure and dynamics of cell membranes: an update of the singer-Nicolson model. Biochim. Biophys. Acta 1838 (2014), 1467–1476.
47. [47] Issack, B.B., Peslherbe, G.H., Effects of cholesterol on the thermodynamics and kinetics of passive transport of water through lipid membranes. J. Phys. Chem. B 119 (2015), 9391–9400.
48. [48] Ulander, J., Haymet, A.D., Permeation across hydrated DPPC lipid bilayers: simulation of the titrable amphiphilic drug valproic acid. Biophys. J. 85 (2003), 3475–3484.
49. [49] Wang, Y., Hu, D., Wei, D., Transmembrane permeation mechanism of charged methyl guanidine. J. Chem. Theory Comput. 10 (2014), 1717–1726.
50. [50] Huster, D., Jin, A.J., Arnold, K., Gawrisch, K., Water permeability of polyunsaturated lipid membranes measured by 17O NMR. Biophys. J. 73 (1997), 855–864.
51. [51] Vorobyov, I., Olson, T.E., Kim, J.H., Koeppe, R.E. 2nd, Andersen, O.S., Allen, T.W., Ion-induced defect permeation of lipid membranes. Biophys. J. 106 (2014), 586–597.
52. [52] van Hell, A.J., Melo, M.N., van Blitterswijk, W.J., Gueth, D.M., Braumuller, T.M., Pedrosa, L.R., Song, J.Y., Marrink, S.J., Koning, G.A., Jonkers, J., Verheij, M., Defined lipid analogues induce transient channels to facilitate drug-membrane traversal and circumvent cancer therapy resistance. Sci. Rep., 3, 2013, 1949.
53. [53] Kim, J.E., Cho, H.J., Kim, J.S., Shim, C.K., Chung, S.J., Oak, M.H., Yoon, I.S., Kim, D.D., The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicin. Xenobiotica 43 (2013), 579–591.
54. [54] Thomae, A.V., Wunderli-Allenspach, H., Krämer, S.D., Permeation of aromatic carboxylic acids across lipid bilayers: the pH-partition hypothesis revisited. Biophys. J. 89 (2005), 1802–1811.
55. [55] Zhang, Y., Boyd, S.A., Teppen, B.J., Tiedje, J.M., Li, H., Role of tetracycline speciation in the bioavailability to Escherichia coli for uptake and expression of antibiotic resistance. Environ. Sci. Technol. 48 (2014), 4893–4900.
56. [56] Thomae, A.V., Koch, T., Panse, C., Wunderli-Allenspach, H., Krämer, S.D., Comparing the lipid membrane affinity and permeation of drug-like acids: the intriguing effects of cholesterol and charged lipids. Pharm. Res. 24 (2007), 1457–1472.
57. [57] Krämer, S.D., Lombardi, D., Primorac, A., Thomae, A.V., Wunderli-Allenspach, H., Lipid-bilayer permeation of drug-like compounds. Chem. Biodivers. 6 (2009), 1900–1916.
58. [58] Miller, J.M., Dahan, A., Gupta, D., Varghese, S., Amidon, G.L., Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. Mol. Pharm. 7 (2010), 1223–1234.
59. [59] Pagliara, A., Testa, B., Carrupt, P.A., Jolliet, P., Morin, C., Morin, D., Urien, S., Tillement, J.P., Rihoux, J.P., Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist. J. Med. Chem. 41 (1998), 853–863.
60. [60] Clegg, W., Teat, S.J., Tetracycline hydrochloride: a synchrotron microcrystal study. Acta Crystallogr. C 56:Pt 11 (2000), 1343–1345.
61. [61] Sjolin-Forsberg, G., Hermansson, J., Comparative bioavailability of tetracycline and lymecycline. Br. J. Clin. Pharmacol. 18 (1984), 529–533.
62. [62] Duarte, H.A., Carvalho, S., Paniago, E.B., Simas, A.M., Importance of tautomers in the chemical behavior of tetracyclinesdagger. J. Pharm. Sci. 88 (1999), 111–120.
63. [63] S.D. Krämer, http://www.biopharmacy.ethz.ch/simulations.html.
64. [64] Choc, M.G., Bioavailability and pharmacokinetics of cyclosporine formulations: neoral vs sandimmune. Int. J. Dermatol. 36:Suppl. 1 (1997), 1–6.
65. [65] Kessler, H., Köck, M., Wein, T., Gehrke, M., Reinvestigation of the conformation of cyclosporin A in chloroform. Helv. Chim. Acta 73 (1990), 1818–1832.
66. [66] Giordanetto, F., Kihlberg, J., Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?. J. Med. Chem. 57 (2014), 278–295.
67. [67] Gupta, D., Varghese Gupta, S., Dahan, A., Tsume, Y., Hilfinger, J., Lee, K.D., Amidon, G.L., Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue. Mol. Pharm. 10 (2013), 512–522.
68. [68] Brandsch, M., Drug transport via the intestinal peptide transporter PepT1. Curr. Opin. Pharmacol. 13 (2013), 881–887.
69. [69] Tashima, T., Intriguing possibilities and beneficial aspects of transporter-conscious drug design. Bioorg. Med. Chem. 23 (2015), 4119–4131.
70. [70] Yu, J., Ritchie, T.K., Mulgaonkar, A., Ragueneau-Majlessi, I., Drug disposition and drug–drug interaction data in 2013 FDA new drug applications: a systematic review. Drug Metab. Dispos. 42 (2014), 1991–2001.
71. [71] Prueksaritanont, T., Chu, X., Gibson, C., Cui, D., Yee, K.L., Ballard, J., Cabalu, T., Hochman, J., Drug–drug interaction studies: regulatory guidance and an industry perspective. AAPS J. 15 (2013), 629–645.
72. [72] Kis, O., Robillard, K., Chan, G.N., Bendayan, R., The complexities of antiretroviral drug–drug interactions: role of ABC and SLC transporters. Trends Pharmacol. Sci. 31 (2010), 22–35.
73. [73] de Lima Toccafondo Vieira, M., Tagliati, C.A., Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools. Expert Opin. Drug Metab. Toxicol. 10 (2014), 581–597.
74. [74] Bohmdorfer, M., Maier-Salamon, A., Riha, J., Brenner, S., Hoferl, M., Jager, W., Interplay of drug metabolizing enzymes with cellular transporters. Wien. Med. Wochenschr. 164 (2014), 461–471.